Efficacy and safety-in analysis of short-course radiation followed by mFOLFOX-6 plus avelumab for locally advanced rectal adenocarcinoma.
Adenocarcinoma
/ drug therapy
Adult
Aged
Antibodies, Monoclonal, Humanized
/ therapeutic use
Antineoplastic Agents, Immunological
/ therapeutic use
Antineoplastic Combined Chemotherapy Protocols
/ therapeutic use
Chemoradiotherapy, Adjuvant
Female
Fluorouracil
/ therapeutic use
Humans
Immunotherapy
Leucovorin
/ therapeutic use
Male
Middle Aged
Neoadjuvant Therapy
Organoplatinum Compounds
/ therapeutic use
Prospective Studies
Rectal Neoplasms
/ drug therapy
Treatment Outcome
Chemotherapy
Immunotherapy
Neo-adjuvant therapy
Radiotherapy
Rectal cancer
Journal
Radiation oncology (London, England)
ISSN: 1748-717X
Titre abrégé: Radiat Oncol
Pays: England
ID NLM: 101265111
Informations de publication
Date de publication:
07 Oct 2020
07 Oct 2020
Historique:
received:
28
04
2020
accepted:
24
09
2020
entrez:
8
10
2020
pubmed:
9
10
2020
medline:
31
7
2021
Statut:
epublish
Résumé
Neoadjuvant chemotherapy and short-course radiotherapy followed by resection has been gaining recognition in the treatment of rectal cancer. Avelumab is a fully human immunoglobulin that binds Programmed Death-Ligand 1 (PD-L1) and prevents the suppression of the cytotoxic T cell immune response. This phase II trial evaluates the safety and pathologic response rate of short-course radiation followed by 6 cycles of mFOLFOX6 with avelumab in patients with locally advanced rectal cancer (LARC). This study is prospective single-arm, multicenter phase II trial adopting Simon's two-stage. Short-course radiation is given over 5 fractions to a total dose of 25 Gy. mFOLFOX6 plus avelumab (10 mg/kg) are given every 2 weeks for 6 cycles. Total mesorectal excision is performed 3-4 weeks after the last cycle of avelumab. Follow up after surgery is done every 3 months to a total of 36 months. Adverse event data collection is recorded at every visit. 13 out of 44 patients with LARC were enrolled in the first stage of the study (30% from total sample size). All patients met the inclusion criteria and received the full short-course radiation course followed by 6 cycles of mFOLFOX6 plus avelumab. 12 out of the 13 patients completed TME while one patient had progression of disease and was dropped out of the study. The sample consisted of 9 (69%) males and 4 (31%) females with median age of 62 (33-73) years. The first interim analysis revealed that 3 (25%) patients achieved pathologic complete response (pCR) (tumor regression grade, TRG 0) out of 12. While 3 (25%) patients had near pCR with TRG 1. In total, 6 out of 12 patients (50%) had a major pathologic response. All patients were found to be MMR proficient. The protocol regimen was well tolerated with no serious adverse events of grade 4 reported. In patients with LARC, neoadjuvant radiation followed by mFOLFOX6 with avelumab is safe with a promising pathologic response rate. Trial Registration Number and Date of Registration ClinicalTrials.gov NCT03503630, April 20, 2018. https://clinicaltrials.gov/ct2/show/NCT03503630?term=NCT03503630&draw=2&rank=1 .
Sections du résumé
BACKGROUND
BACKGROUND
Neoadjuvant chemotherapy and short-course radiotherapy followed by resection has been gaining recognition in the treatment of rectal cancer. Avelumab is a fully human immunoglobulin that binds Programmed Death-Ligand 1 (PD-L1) and prevents the suppression of the cytotoxic T cell immune response. This phase II trial evaluates the safety and pathologic response rate of short-course radiation followed by 6 cycles of mFOLFOX6 with avelumab in patients with locally advanced rectal cancer (LARC).
METHODS
METHODS
This study is prospective single-arm, multicenter phase II trial adopting Simon's two-stage. Short-course radiation is given over 5 fractions to a total dose of 25 Gy. mFOLFOX6 plus avelumab (10 mg/kg) are given every 2 weeks for 6 cycles. Total mesorectal excision is performed 3-4 weeks after the last cycle of avelumab. Follow up after surgery is done every 3 months to a total of 36 months. Adverse event data collection is recorded at every visit.
RESULTS
RESULTS
13 out of 44 patients with LARC were enrolled in the first stage of the study (30% from total sample size). All patients met the inclusion criteria and received the full short-course radiation course followed by 6 cycles of mFOLFOX6 plus avelumab. 12 out of the 13 patients completed TME while one patient had progression of disease and was dropped out of the study. The sample consisted of 9 (69%) males and 4 (31%) females with median age of 62 (33-73) years. The first interim analysis revealed that 3 (25%) patients achieved pathologic complete response (pCR) (tumor regression grade, TRG 0) out of 12. While 3 (25%) patients had near pCR with TRG 1. In total, 6 out of 12 patients (50%) had a major pathologic response. All patients were found to be MMR proficient. The protocol regimen was well tolerated with no serious adverse events of grade 4 reported.
CONCLUSION
CONCLUSIONS
In patients with LARC, neoadjuvant radiation followed by mFOLFOX6 with avelumab is safe with a promising pathologic response rate. Trial Registration Number and Date of Registration ClinicalTrials.gov NCT03503630, April 20, 2018. https://clinicaltrials.gov/ct2/show/NCT03503630?term=NCT03503630&draw=2&rank=1 .
Identifiants
pubmed: 33028346
doi: 10.1186/s13014-020-01673-6
pii: 10.1186/s13014-020-01673-6
pmc: PMC7542723
doi:
Substances chimiques
Antibodies, Monoclonal, Humanized
0
Antineoplastic Agents, Immunological
0
Organoplatinum Compounds
0
avelumab
KXG2PJ551I
Leucovorin
Q573I9DVLP
Fluorouracil
U3P01618RT
Banques de données
ClinicalTrials.gov
['NCT03503630']
Types de publication
Clinical Trial, Phase II
Journal Article
Multicenter Study
Langues
eng
Sous-ensembles de citation
IM
Pagination
233Références
Mod Pathol. 2018 Feb;31(2):214-234
pubmed: 29192647
J Natl Compr Canc Netw. 2018 May;16(5S):617-619
pubmed: 29784739
JAMA Oncol. 2018 Jun 14;4(6):e180071
pubmed: 29566109
Control Clin Trials. 1989 Mar;10(1):1-10
pubmed: 2702835
BMC Cancer. 2015 Oct 23;15:767
pubmed: 26497495
CA Cancer J Clin. 2019 Jan;69(1):7-34
pubmed: 30620402
BMC Cancer. 2013 Jun 07;13:279
pubmed: 23742033
Dis Colon Rectum. 2018 Oct;61(10):1146-1155
pubmed: 30192323
Clin Cancer Res. 2009 Sep 1;15(17):5379-88
pubmed: 19706802
Int J Radiat Biol. 2019 Jul;95(7):936-939
pubmed: 31120369
J Clin Oncol. 2016 Sep 1;34(25):3039-46
pubmed: 27432916
J Clin Oncol. 2011 Dec 10;29(35):4633-40
pubmed: 22067400
Cancer Res. 2014 Oct 1;74(19):5458-68
pubmed: 25274032
CA Cancer J Clin. 2018 Nov;68(6):394-424
pubmed: 30207593
J Clin Oncol. 2012 Jun 1;30(16):1926-33
pubmed: 22529255
Int J Radiat Oncol Biol Phys. 2006 Nov 15;66(4):1219-27
pubmed: 17145537
N Engl J Med. 2015 Jun 25;372(26):2509-20
pubmed: 26028255
World J Gastroenterol. 2019 Aug 7;25(29):3920-3928
pubmed: 31413527
Clin Cancer Res. 2005 Jan 15;11(2 Pt 1):728-34
pubmed: 15701862
Cancer. 2008 Jul 1;113(1):57-64
pubmed: 18442099
Ann Oncol. 2015 Aug;26(8):1722-8
pubmed: 25957330
Semin Radiat Oncol. 2016 Jul;26(3):205-10
pubmed: 27238472